<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04000373</url>
  </required_header>
  <id_info>
    <org_study_id>19-580</org_study_id>
    <nct_id>NCT04000373</nct_id>
  </id_info>
  <brief_title>Pilot Study of Powered Exoskeleton Use for Gait Rehabilitation in Individuals With Multiple Sclerosis</brief_title>
  <official_title>Pilot Study of Powered Exoskeleton Use for Gait Rehabilitation in Individuals With Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigator plans to test the use of the Ekso Bionics® Gait Training (Ekso GT™)
      exoskeleton for gait training in MS patients. The device will solely be used in the clinic
      under direct supervision from a physical therapist. This is a small PI-initiated uncontrolled
      pilot study to gather safety and feasibility data on the exoskeleton in individuals with MS
      and walking impairment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Powered exoskeletons are approved by the FDA to assist in the rehabilitation of persons with
      spinal cord injury and post-stroke hemiplegia. The investigator is aware of only one pilot
      study of a powered exoskeleton (ReWalk®) in multiple sclerosis (MS) which demonstrated some
      improvements in sitting, standing and walking posture when used consistently. The
      investigator is not aware of any study of the Ekso GT™ exoskeleton in MS.

      This is a feasibility and safety study of using the Ekso GT™ exoskeleton for gait training in
      patients with relapsing or progressive MS and severe mobility limitations (EDSS 5-5 - 7.5).
      Preliminary efficacy outcomes on gait and walking will also be collected for the purpose of
      designing a larger clinical trial of the Ekso GT™ exoskeleton for gait training in patients
      with MS.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 23, 2019</start_date>
  <completion_date type="Actual">January 9, 2020</completion_date>
  <primary_completion_date type="Actual">January 9, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>uncontrolled pre-post intervention study of the use of the Ekso GT™exoskeleton in gait training in the MS population</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dropout Rate</measure>
    <time_frame>0-14 weeks</time_frame>
    <description>Percentage of enrolled participants who drop out of the study before the end of the treatment period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>0-14 weeks</time_frame>
    <description>.All adverse events were collected throughout the study for each participant, up to 14 weeks&quot;,</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Timed 25 Foot Walk</measure>
    <time_frame>0-14 weeks</time_frame>
    <description>Change in walking speed on the Timed 25 Foot Walk between baseline, end of treatment, and end of follow-up period.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Multiple Sclerosis</condition>
  <condition>Gait Disorders, Neurologic</condition>
  <arm_group>
    <arm_group_label>gait training with exoskeleton device</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>uncontrolled pre-post intervention study of gait training using the Ekso GT™exoskeleton</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ekso GT™ exoskeleton</intervention_name>
    <description>The rehabilitation treatment will consist of 3 sessions per week for 8 weeks, for a total of 24 sessions. Missed sessions will be made up if possible. Each session will be scheduled for 60 minutes, and will consist of stretching, overground gait training, and gait training with the study device. Rest periods will be provided as necessary during the training visits.</description>
    <arm_group_label>gait training with exoskeleton device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of MS per 2017 revised McDonald criteria

          -  EDSS score 5.5-7.5 (moderate to severe walking disability)

          -  Cleared for gait training with the study device by the study treating physician

        Device-Specific Criteria

          -  Involved in a standing program or must be able to tolerate at least 15 min upright
             without signs or symptoms of orthostatic hypotension

          -  Weigh 220 pounds (100kg) or less

          -  Be able to fit into the Ekso device:

          -  Between approximately 5'0&quot; and 6'4&quot; tall (really depends on leg measurements)

          -  Sufficient diaphragmatic strength such that respiration is not compromised with
             exercise

        Assessed by physical therapy:

          -  Standing hip width of approximately 18&quot; or less

          -  Have near normal range of motion(ROM) in hips, knees and ankles

          -  Sufficient upper extremity strength to use a front wheeled walker by manual muscle
             testing (minimum triceps strength bilaterally of 3/5, shoulder abduction and
             flexion/extension of 4/5 OR as discussed during demo, 2 normally functioning limbs
             such as in hemiplegia)

        Exclusion Criteria:

          -  • MS exacerbation, severe acute comorbidity or surgery less than 90 days prior to
             enrollment

               -  Diagnosed with osteoporosis or history of long bone fractures since diagnosis

               -  Safety concern due to neurologic impairments (e.g. upper extremity weakness,
                  visual loss) or comorbidities (e.g. cardiac, respiratory)

               -  Other neurologic or non-neurologic condition interfering with walking

               -  &lt; 1 month since previous intensive gait training regimen or initiation of
                  treatment that can affect walking (e.g. medication for spasticity)

               -  Planned change in medications that may affect walking during the study period

               -  Uncontrolled or severe orthostatic hypotension that limits standing tolerance

               -  Active heterotrophic ossification (HO), hip dysplasia, or uncontrolled hip/knee
                  axis abnormalities

               -  Score &lt;22 on the Mini-Mental State Examination or deemed to have cognitive
                  impairment precluding safe training with the device during the screening and
                  training process

               -  Colostomy

               -  Pregnancy

               -  Unresolved deep vein thrombosis

               -  Uncontrolled autonomic dysreflexia

               -  Currently involved in another rehabilitation study

        Assessed by physical therapy:

          -  Severe spasticity that prevents joint motion (severe stiffness or rigidity) in
             proximal lower extremity muscles, including hip adductors and knee flexors/extensors.

          -  Hip flexion contracture greater than ~17°

          -  Knee flexion contracture greater than 12°

          -  Unable to achieve neutral ankle dorsiflexion with passive stretch (achieve neutral
             with up to 12° knee flexion)

          -  Leg length discrepancy greater than 0.5&quot; for upper leg, greater than 0.75&quot; for lower
             leg

          -  Spinal instability

          -  Severe muscular or skeletal pain

          -  Open skin ulcerations on buttocks or other body surfaces in contact with exoskeleton
             or harness

          -  Shoulder extension range of motion(ROM) &lt; 50° excludes using crutches during sit to
             stand or vice versa. (Walking with crutches permitted, sit &lt;&gt; stand would be done with
             walker
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francois A Bethoux, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic Neurological Institute Mellen Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>June 6, 2019</study_first_submitted>
  <study_first_submitted_qc>June 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 27, 2019</study_first_posted>
  <results_first_submitted>February 25, 2020</results_first_submitted>
  <results_first_submitted_qc>February 25, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 13, 2020</results_first_posted>
  <last_update_submitted>March 26, 2020</last_update_submitted>
  <last_update_submitted_qc>March 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>Francois Bethoux, MD</investigator_full_name>
    <investigator_title>Director of Rehabilitation Services at the Cleveland Clinic Mellen Center.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Gait Disorders, Neurologic</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Nervous System Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 17, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/73/NCT04000373/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited and enrolled between July 2019 and October 2019 in the outpatient clinic.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Gait Training With Exoskeleton Device</title>
          <description>uncontrolled pre-post intervention study of gait training using the Ekso GT™exoskeleton
Ekso GT™ exoskeleton: The rehabilitation treatment will consist of 3 sessions per week for 8 weeks, for a total of 24 sessions. Missed sessions will be made up if possible. Each session will be scheduled for 60 minutes, and will consist of stretching, overground gait training, and gait training with the study device. Rest periods will be provided as necessary during the training visits.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Gait Training With Exoskeleton Device</title>
          <description>uncontrolled pre-post intervention study of gait training using the Ekso GT™exoskeleton
Ekso GT™ exoskeleton: The rehabilitation treatment will consist of 3 sessions per week for 8 weeks, for a total of 24 sessions. Missed sessions will be made up if possible. Each session will be scheduled for 60 minutes, and will consist of stretching, overground gait training, and gait training with the study device. Rest periods will be provided as necessary during the training visits.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>The Expanded Disability Status Scale = 5.5 to 7.5.Range from 0 to 10, higher scores worse outcome</title>
          <description>The Expanded Disability Status Scale (EDSS) is a comprehensive, quantitative neurological examination, and is the most widely used measure of MS-related disability for clinical and research purposes. Scores range from 0 to 10, with higher scores representing a worse outcome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.30" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Dropout Rate</title>
        <description>Percentage of enrolled participants who drop out of the study before the end of the treatment period.</description>
        <time_frame>0-14 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gait Training With Exoskeleton Device</title>
            <description>uncontrolled pre-post intervention study of gait training using the Ekso GT™exoskeleton
Ekso GT™ exoskeleton: The rehabilitation treatment will consist of 3 sessions per week for 8 weeks, for a total of 24 sessions. Missed sessions will be made up if possible. Each session will be scheduled for 60 minutes, and will consist of stretching, overground gait training, and gait training with the study device. Rest periods will be provided as necessary during the training visits.</description>
          </group>
        </group_list>
        <measure>
          <title>Dropout Rate</title>
          <description>Percentage of enrolled participants who drop out of the study before the end of the treatment period.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adverse Events</title>
        <description>.All adverse events were collected throughout the study for each participant, up to 14 weeks&quot;,</description>
        <time_frame>0-14 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gait Training With Exoskeleton Device</title>
            <description>uncontrolled pre-post intervention study of gait training using the Ekso GT™exoskeleton
Ekso GT™ exoskeleton: The rehabilitation treatment will consist of 3 sessions per week for 8 weeks, for a total of 24 sessions. Missed sessions will be made up if possible. Each session will be scheduled for 60 minutes, and will consist of stretching, overground gait training, and gait training with the study device. Rest periods will be provided as necessary during the training visits.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>.All adverse events were collected throughout the study for each participant, up to 14 weeks&quot;,</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Timed 25 Foot Walk</title>
        <description>Change in walking speed on the Timed 25 Foot Walk between baseline, end of treatment, and end of follow-up period.</description>
        <time_frame>0-14 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gait Training With Exoskeleton Device</title>
            <description>uncontrolled pre-post intervention study of gait training using the Ekso GT™exoskeleton
Ekso GT™ exoskeleton: The rehabilitation treatment will consist of 3 sessions per week for 8 weeks, for a total of 24 sessions. Missed sessions will be made up if possible. Each session will be scheduled for 60 minutes, and will consist of stretching, overground gait training, and gait training with the study device. Rest periods will be provided as necessary during the training visits.</description>
          </group>
        </group_list>
        <measure>
          <title>Timed 25 Foot Walk</title>
          <description>Change in walking speed on the Timed 25 Foot Walk between baseline, end of treatment, and end of follow-up period.</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to end of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.72" spread="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to end of follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.24" spread="2.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>all adverse events were collected throughout the study for each participant, up to 14 weeks.</time_frame>
      <desc>All probable and possibly related to device use events were collected along with other adverse events including falls</desc>
      <group_list>
        <group group_id="E1">
          <title>Gait Training With Exoskeleton Device</title>
          <description>uncontrolled pre-post intervention study of gait training using the Ekso GT™exoskeleton
Ekso GT™ exoskeleton: The rehabilitation treatment will consist of 3 sessions per week for 8 weeks, for a total of 24 sessions. Missed sessions will be made up if possible. Each session will be scheduled for 60 minutes, and will consist of stretching, overground gait training, and gait training with the study device. Rest periods will be provided as necessary during the training visits.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Low back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Chest wall soreness</sub_title>
                <description>Subsequent to a fall</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <description>None of the falls occurred during treatment visits.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Back muscle weakness</sub_title>
                <description>assessed as related to MS</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Research Nurse Coordinator</name_or_title>
      <organization>Cleveland Clinic Neurological Institute Mellen Center</organization>
      <phone>216-445-5877</phone>
      <email>stoughd@ccf.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

